Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab

BMC Hematology

Carsten S Larsen⁴  Peter Hokland¹  Marianne Hokland⁵  Karsten H Gadegaard²  Charlotte Nyvold¹  Mikkel S Petersen³  Charlotte C Petersen⁵  Jens Magnus Bernth-Jensen³  Trine H Mogensen⁴ 

[1] Department of Haematology, Aarhus University Hospital, Aarhus, Denmark;Department of Anaesthesiology, Aarhus University Hospital, Aarhus, Denmark;Department of Clinical Immunology, Aarhus University Hospital, Skejby, Aarhus, Denmark;International Center for Immunodeficiency Diseases, Aarhus University Hospital, Skejby, Aarhus, Denmark;Department of Biomedicine, Aarhus University, Aarhus, Denmark

关键词: Rituximab;    Immune thrombocytopenic purpura;    Common variable immunodeficiency;    Hypogammaglobulinemia;   

Others  :  865384
DOI  :  10.1186/2052-1839-13-4

 received in 2012-05-27, accepted in 2012-12-18,  发布年份 2013

【 摘 要 】

Background

Hypogammaglobulinemia may be part of several different immunological or malignant conditions, and its origin is not always obvious. Furthermore, although autoimmune cytopenias are known to be associated with common variable immunodeficiency (CVID) and even may precede signs of immunodeficiency, this is not always recognized. Despite novel insight into the molecular immunology of common variable immunodeficiency, several areas of uncertainty remain. In addition, the full spectrum of immunological effects of the B cell depleting anti-CD20 antibody Rituximab has not been fully explored. To our knowledge this is the first report of development of CVID in a patient with normal immunoglobulin prior to Rituximab treatment.

Case presentation

Here we describe the highly unusual clinical presentation of a 34-year old Caucasian male with treatment refractory immune thrombocytopenic purpura and persistent lymphadenopathy, who was splenectomized and received multiple courses of high-dose corticosteroid before treatment with Rituximab resulted in a sustained response. However, in the setting of severe pneumococcal meningitis, hypogammaglobulinemia was diagnosed. An extensive immunological investigation was performed in order to characterize his immune status, and to distinguish between a primary immunodeficiency and a side effect of Rituximab treatment. We provide an extensive presentation and discussion of the literature on the basic immunology of CVID, the mechanism of action of Rituximab, and the immunopathogenesis of hypogammaglobulinemia observed in this patient.

Conclusions

We suggest that CVID should be ruled out in any patient with immune cytopenias in order to avoid diagnostic delay. Likewise, we stress the importance of monitoring immunoglobulin levels before, during, and after Rituximab therapy to identify patients with hypogammaglobulinemia to ensure initiation of immunoglobulin replacement therapy in order to avoid life-threatening invasive bacterial infections. Recent reports indicate that Rituximab is not contra-indicated for the treatment of CVID-associated thrombocytopenia, however concomitant immunoglobulin substitution therapy is of fundamental importance to minimize the risk of infections. Therefore, lessons can be learned from this case report by clinicians caring for patients with immunodeficiencies, haematological diseases or other autoimmune disorders, particularly, when Rituximab treatment may be considered.

【 授权许可】

   
2013 Mogensen et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, et al.: Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007, 120:776-794.
• [2]Yong PF, Thaventhiran JE, Grimbacher B: "A rose is a rose is a rose," but CVID is Not CVID commonvariable immune deficiency (CVID), what do we know in 2011. Adv Immunol 2011, 111:47-107.
• [3]Cunningham-Rundles C: Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008, 28:S42-S45.
• [4]Stasi R: Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010, 47:170-179.
• [5]Russell TB, Kurre P: Double-negative T cells are non-ALPS-specific markers of immune dysregulation found in patients with aplastic anemia. Blood 2010, 116:5072-5073.
• [6]Garcia-Dabrio MC, Pujol-Moix N, Martinez-Perez A, Fontcuberta J, Souto JC, Soria JM, et al.: Influence of age, gender and lifestyle in lymphocyte subsets: report from the Spanish Gait-2 Study. Acta Haematol 2012, 127:244-249.
• [7]Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al.: Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008, 112:277-286.
• [8]Warnatz K, Denz A, Drager R, Braun M, Groth C, Wolff-Vorbeck G, et al.: Severe deficiency of switched memory B cells (CD27(+)IgM(−)IgD(−)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 2002, 99:1544-1551.
• [9]Mouillot G, Carmagnat M, Gerard L, Garnier JL, Fieschi C, Vince N, et al.: B-Cell and T-Cell Phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol 2010, 30:746-755.
• [10]Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al.: The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008, 111:77-85.
• [11]Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C: High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol 2007, 124:182-189.
• [12]Bonhomme D, Hammarstrom L, Webster D, Chapel H, Hermine O, Le Deist F, et al.: Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J Immunol 2000, 165:4725-4730.
• [13]Agarwal S, Cunningham-Rundles C: Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009, 9:347-352.
• [14]Notarangelo LD: Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematology Am Soc Hematol Educ Program 2009, 2009:139-143.
• [15]Orange JS, Glessner JT, Resnick E, Sullivan KE, Lucas M, Ferry B, et al.: Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol 2011, 127:1360-1U79.
• [16]Wang J, Cunningham-Rundles C: Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005, 25:57-62.
• [17]Michel M, Chanet V, Galicier L, Ruivard M, Levy Y, Hermine O, et al.: Autoimmune thrombocytopenic purpura and common variable immunodeficiency - analysis of 21 cases and review of the literature. Medicine 2004, 83:254-263.
• [18]Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al.: Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998, 9:995-1001.
• [19]Levesque MC: Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 2009, 157:198-208.
• [20]Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, et al.: Multiple courses of Rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012. Epub ahead of print
• [21]He D, Zhou H, Han W, Zhang S: Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2011, 7:CD009130.
• [22]Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, et al.: Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012. Epub ahead of print
• [23]Gregersen JW, Jayne DR: B-cell depletion in te treatment of lupus nephritis. Nat Rev Nephrol 2012, 8:505-514.
• [24]Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al.: Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-W5.
• [25]Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al.: International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
• [26]Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F: Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003, 121:913-918.
• [27]Gurcan HM, Keskin DB, Stern JNH, Nitzberg MA, Shekhani H, Ahmed AR: A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009, 9:10-25.
• [28]Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, et al.: Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 2011, 155:498-508.
• [29]Tedder TE, Engel P: Cd20 - a regulator of cell-cycle progression of B-lymphocytes. Immunol Today 1994, 15:450-454.
• [30]Hultin LE, Hausner MA, Hultin PM, Giorgi JV: Cd20 (Pan-B Cell) antigen is expressed at a low-level on a subpopulation of human lymphocytes-T. Cytometry 1993, 14:196-204.
• [31]van der Kolk LE, Baars JW, Prins MH, Van Oers MHJ: Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002, 100:2257-2259.
• [32]Andemariam B, Bussel J: New therapies for immune thrombocytopenic purpura. Curr Opin Hematol 2007, 14:427-431.
• [33]Slifka MK, Antia R, Whitmire JK, Ahmed R: Humoral immunity due to long-lived plasma cells. Immunity 1998, 8:363-372.
• [34]Van Vollenhoven R, Bessette L, Emery P: Long-term safety of rituximab: long-term follow-up of the RA clinical trials and retreatment population. J Rheumatol 2010, 37:1320.
• [35]Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, et al.: Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 2008, 26:431-433.
• [36]Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, et al.: Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol 2006, 77:226-232.
• [37]Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al Ghanmi F, et al.: Does rituximab aggravate pre-existing hypogammaglobulinaemia. J Clin Pathol 2010, 63:275-277.
• [38]Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M, et al.: Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 2005, 75:527-529.
• [39]Carbone J, Escudero A, Mayayo M, Ballesteros M, Perez-Corral A, Sanchez-Ramon S, et al.: Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency. Ann Ny Acad Sci 2005, 1051:666-671.
• [40]Al Ahmad M, Al Rasheed M, Al Muhani A: Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency. J Investig Allergol Clin Immunol 2010, 20:259-262.
• [41]Mahevas M, Le Page L, Salle V, Cevallos R, Smail A, Duhaut P, et al.: Efficiency of rituximab in the treatment of autoimmune thrombocytopenic purpura associated with common variable immunodeficiency. Am J Hematol 2006, 81:645-646.
• [42]El Shanawany TM, Williams PE, Jolles S: Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. J Clin Pathol 2007, 60:715-716.
• [43]Rensing-Ehl A, Warnatz K, Fuchs S, Schlesier M, Salzer U, Draeger R, et al.: Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. Clin Immunol 2010, 137:357-365.
• [44]Kuijpers TW, Baars PA, De Kerk DJA, Jansen MH, Dors N, Van Lier RAW, et al.: Common variable immunodeficiency and hemophagocytic features associated with a FAS gene mutation. J Allergy Clin Immunol 2011, 127:1411-1414.
• [45]Martinez-Gamboa L, Mei H, Loddenkemper C, Ballmer B, Hansen A, Lipsky PE, et al.: Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin Immunol 2009, 130:199-212.
• [46]Carbone J, Sarmiento E, Rodriquez-Molina JJ, Fernandez-Cruz E: Atypical presentation of common variable immunodeficiency without infections. Allergol Immunopathol 2004, 32:218-222.
• [47]Seve P, Broussolle C, Pavic M: Primary immunodeficiencies presenting with autoimmune cytopenias in adults. Rev Med Interne 2012. Epub ahead of print